Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Psyence Biomedical Ltd. Common Shares (PBM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PBM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.36% | Avg. Invested days 184 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.86M USD | Price to earnings Ratio 0.12 | 1Y Target Price - |
Price to earnings Ratio 0.12 | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.15 | 52 Weeks Range 2.94 - 466.80 | Updated Date 06/29/2025 |
52 Weeks Range 2.94 - 466.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 41.76 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -54.2% | Return on Equity (TTM) - |
Valuation
Trailing PE 0.12 | Forward PE - | Enterprise Value 3432164 | Price to Sales(TTM) - |
Enterprise Value 3432164 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 3.35 | Shares Outstanding 583263 | Shares Floating 71171 |
Shares Outstanding 583263 | Shares Floating 71171 | ||
Percent Insiders 0.48 | Percent Institutions 11.13 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Psyence Biomedical Ltd. Common Shares
Company Overview
History and Background
Psyence Biomedical Ltd. is a life science biotechnology company pioneering the use of psychedelic compounds in mental health. Details regarding its precise founding year and early milestones require consulting primary sources and company filings as information is limited in general sources. The company focuses on the research, development, and commercialization of psychedelic-derived medicines.
Core Business Areas
- Psychedelic Medicine Research and Development: Focuses on developing novel treatments for mental health conditions using psychedelic compounds like psilocybin.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its psychedelic-based therapies.
- Drug Commercialization: Aims to commercialize approved psychedelic medicines for widespread patient access.
Leadership and Structure
Details regarding the specific leadership team and organizational structure require consulting the company's official website and regulatory filings. Generally, it includes a CEO, CFO, and a board of directors overseeing the company's operations and strategic direction.
Top Products and Market Share
Key Offerings
- Psilocybin-based Therapies (In Development): Psyence is developing psilocybin-based therapies for mental health disorders. Market share data is not yet available as products are still in development. Competitors include companies researching and developing psychedelic therapies, such as COMPASS Pathways (CMPS), Mind Medicine (MNMD), and Atai Life Sciences (ATAI).
Market Dynamics
Industry Overview
The psychedelic medicine industry is emerging, driven by increasing awareness of mental health challenges and the potential of psychedelic compounds to address these issues. Regulatory landscapes are evolving, with some regions showing greater openness to psychedelic therapies.
Positioning
Psyence Biomedical Ltd. is positioned as a pioneer in the psychedelic medicine space, focusing on rigorous research and clinical development to establish the safety and efficacy of its therapies. They are actively pursuing regulatory approvals to bring these treatments to market.
Total Addressable Market (TAM)
The total addressable market for mental health treatments is substantial, estimated to be in the tens of billions of dollars. Psyence is positioning itself to capture a portion of this market by developing innovative psychedelic-based therapies and establishing a strong presence in the emerging psychedelic medicine landscape.
Upturn SWOT Analysis
Strengths
- Focus on psychedelic medicine research and development
- Experienced management team (assumed based on company focus)
- Intellectual property related to psychedelic therapies
- First mover advantage in a rapidly growing market
Weaknesses
- Early stage company with limited revenue
- High research and development costs
- Regulatory uncertainty surrounding psychedelic medicines
- Reliance on successful clinical trial outcomes
Opportunities
- Regulatory approvals for psychedelic therapies
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing awareness and acceptance of psychedelic medicine
Threats
- Competition from other psychedelic medicine companies
- Unfavorable regulatory changes
- Negative public perception of psychedelic drugs
- Clinical trial failures
Competitors and Market Share
Key Competitors
- CMPS
- MNMD
- ATAI
Competitive Landscape
Psyence Biomedical Ltd. competes with other companies in the psychedelic medicine space. Its competitive advantage lies in its specific research focus, intellectual property portfolio, and ability to navigate the regulatory landscape. Disadvantages include its smaller size and limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's early stage.
Future Projections: Future growth projections are dependent on the successful development and commercialization of its psychedelic therapies. Analyst estimates are not readily available for this specific company.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials, partnerships with research institutions, and efforts to engage with regulators regarding the approval of psychedelic medicines. Specific details require consulting company announcements.
Summary
Psyence Biomedical Ltd. is a promising early-stage company in the burgeoning psychedelic medicine industry. Its focus on research and development offers significant potential, but it faces risks associated with regulatory hurdles, clinical trial outcomes, and competition. The company needs to focus on securing funding, demonstrating clinical efficacy, and navigating the evolving regulatory landscape to achieve long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Industry reports
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on general industry estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Psyence Biomedical Ltd. Common Shares
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2024-01-25 | CEO & Director Dr. Neil Maresky M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.psyencebiomed.com |
Full time employees 12 | Website https://www.psyencebiomed.com | ||
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.